Israeli biomed company Evogene, which genetically engineers plant seeds, is in talks to go public on Nasdaq at a company value of $250 million. Calcalist reports that the IPO will be led by Deutsche Bank and Credit Swiss. Evogene is currently being traded in the Tel Aviv stock exchange at a company value of $210 million.
Related posts
UN Honors Israeli Food Exec For Sustainability Work
September 26, 2023
Startup Unveils Tech To Speed Up Growth Of Cultivated Meat
September 26, 2023
Israel Invests Millions To Help AI Comprehend Hebrew, Arabic
September 21, 2023
Cybersecurity Startup Cato Raises $238M With $3B Valuation
September 21, 2023
Facebook comments